Eli Lilly CEO Dave Ricks presented at the JPMorgan Healthcare Conference. The transcript became available on January 14, 2026. Ricks set a positive tone for investors, noting that 2026 marks the company's 150th anniversary.
The presentation followed positive regulatory news issued the previous day. On January 13, the U.S. Food and Drug Administration (FDA) concluded that warnings regarding suicidal thoughts are not warranted on the labels of GLP-1 weight-loss drugs.
This ruling specifically covers medications including Lilly’s Zepbound. The agency’s comprehensive review found no evidence of an increased risk of suicide associated with the drug class.